Introduction
Chronic arterial hypertension increases left ventricular pressure work, which leads to an increase in left ventricular mass. In hypertensive patients, development of left ventricular hypertrophy (LVH) is related to greater cardiovascular morbidity and mortality. In addition, both electro-and echocardiographically detected LVH is associated with sudden cardiac death. 1, 2 LVH is associated with the occurrence of ventricular tachyarrhythmias, a fact which may in part explain the higher incidence of sudden cardiac death in hypertensive patients. 3 Although detection of LVH is associated with an adverse outcome, it is not a specific predictor of life-threatening ventricular tachyarrhythmias. The currently available non-invasive arrhythmia risk assessment methods, for example, late potentials and heart rate variability, have limited clinical usefulness in hypertensive patients.
Background and rationale
In experimental studies, increase in left ventricular mass creates dispersion of ventricular refractoriness and repolarisation times. 4 Non-homogeneity in ventricular repolarisation predisposes to malignant ventricular tachyarrhythmias. 5 Furthermore, regression of LVH normalises ventricular electrophysiology, and decreases vulnerability to ventricular arrhythmias. 6 Myocardial hypertrophy in response to 7, 8 In response to therapy, the regression of LVH may not coincide with involution of interstitial fibrosis.
Treatment of elevated blood pressure is expected to regress LVH and decrease the risk of sudden cardiac death. In the ASCOT study, both amlodipinebased (calcium-channel blocker) and atenolol-based (beta-adrenergic blocker) antihypertensive drug treatment strategies on outcome in hypertensive patients will be prospectively studied. Both drugs may exert acutely direct effects on ventricular repolarisation unrelated to the anatomic changes resulting from blood pressure control. These direct effects need to be studied on a short-term basis. By lowering blood pressure, these drugs may also cause regression of LVH and its sequelae, and can thus alter ventricular repolarisation on a long-term basis.
The T wave of the electrocardiogram (ECG) is generated by local differences in ventricular repolarisation times. 9 The QT interval in the 12-lead ECG is the clinical counterpart of the ventricular action potential duration. Prolongation of the QT interval reflects delayed repolarisation at least in some parts of the ventricular myocardium. Interlead differences in QT interval durations among different ECG leads, called QT dispersion, may indirectly reflect inhomogeneity in ventricular repolarisation times. 10, 11 In clinical studies, LVH has been associated with an increase in QT dispersion. [12] [13] [14] In hypertensive patients, increased QT dispersion was a predictor of the occurrence of ventricular arrhythmias, 15 and regression of LVH was associated with a decrease in QT dispersion. 16 Therefore, analysis of the QT interval duration and dispersion in hypertensive patients may give clinically useful information of altered ventricular repolarisation which may be important for arrhythmic vulnerability.
Objectives
In this sub-study, we aim to compare the short-and long-term effects of amlodipine-based and atenololbased antihypertensive regimens on QT dispersion, and to study whether the possible changes are related to LVH measures in 12-lead ECG. Furthermore, we aim to assess whether baseline QT dispersion is associated with the risk of sudden cardiac death during the 5-year follow-up in a cohort of the ASCOT study.
Study methods and design
The short-term (baseline vs 6-week ECG's) and longterm (baseline vs 2-and 5-year ECG's) impact of the two antihypertensive regimens on measures of QT dispersion will be examined in all 2000 participants of the Finnish cohort of the ASCOT study population. For the patients who suffer sudden cardiac death during the follow-up, controls will be matched from the survivors in a nested case-control design in an attempt to control for potential confounding factors.
QT dispersion measurements will be made from ECG's recorded at baseline, 6 weeks, 2 years and 5 years. The ECG's will be recorded at rest in supine position with a paper speed of 50 mm/s, an amplitude calibration of 10 mm/mV, and six simultaneous leads. Two ECG's will be printed, one for the ASCOT Core Centre and the other one for the substudy centre located in the Helsinki University Central Hospital. The participating centres have received instructions of the ECG recording procedure from the coordinating sub-study centre to ensure high quality ECG's.
On a digitising board, the following time-points will be digitised: beginning of QRS, J point, T wave apex and T wave end (defined as the return to T-P baseline), R wave amplitude, S wave amplitude, and T wave amplitude. Two consecutive QRS-T complexes will be measured. The digitising table is connected to a personal computer to automatically calculate QRS duration, QTend interval, and QTapex interval in each lead. These will be displayed on the monitor so that errors in the digitisation procedure can be corrected before saving the values into a database. An average of the time intervals from the two measured complexes will be used for final analyses. Measures of QT dispersion will be calculated as: (1) the difference between maximum and minimum of QT interval measures, and (2) the standard deviation of QT interval measures in all the 12 leads. For final analysis, the QT intervals will be corrected for heart rate, whereas QT dispersion measures will not be rate-corrected. The ECG LVH indices will be calculated using the Sokolow-Lyon, Cornell voltage, and Cornell voltage product indices. 17 All participants in the national cohort of the ASCOT study (2000 patients) will be recruited for this sub-study. Patients who show complete bundle branch block or other than sinus rhythm in the ECG will be excluded from the QT dispersion measurements. There will be no additional patient contacts other than the ones needed for the main study. At the 6-week visit, an extra ECG will be recorded not included in the main ASCOT study protocol.
Discussion
This sub-study of the ASCOT study will show whether amlodipine-based and atenolol-based antihypertensive treatment has an effect on QT dispersion. The effect will be evaluated on a short-term basis, which may reveal a direct effect of the drug on ventricular repolarisation, and on a long-term basis. The latter is related also to the evolution of ECG LVH criteria. Furthermore, this sub-study also examines the relationship of baseline QT interval and QT dispersion measures to unfavourable outcome, particularly sudden cardiac death. Therefore, this sub-study will contribute to the evaluation of the clinical value of measures of QT dispersion as indicators of arrhythmic risk and of beneficial therapeutic response in hypertensive patients.
Changes in ECG LVH criteria can be used to assess regression of anatomic LVH. 18 Although changes in left ventricular mass are more reliably quantified with serial echocardiographic measurements, for large multicentre studies these are impractical.
The QT interval has clinical significance as a reflector of prolongation of repolarisation time in ventricular myocardium, which in hypertensive patients may herald increased risk of arrhythmias based on re-entry and possibly on afterdepolarisations as well. QT dispersion as a direct index of ventricular repolarisation dispersion has been questioned, 19 however. The T wave on the body surface ECG is generated by differences in repolarisation times across the myocardial wall. 9 Therefore, pathophysiological factors changing the ventricular repolarisation may alter the T wave morphology. 20 Measures of QT dispersion seem to bear some relation to variation in the timing of local repolarisation, 10, 11 but may in fact be an indirect way of characterising altered T wave morphology. 21 Nonetheless, QT dispersion may be useful for screening patients at risk of sudden cardiac death. 22 Furthermore, in this sub-study, various other measures of T wave duration and amplitude will also be studied.
